USP24 and neoplasm: The data indicated that the tumor area in the gefitinib-induced EGFRL858R*USP24C1695A drug-resistant mice was inhibited compared with that in the gefitinib-induced EGFRL858R*USP24WT drug-resistant mice, indicating that USP24 promotes drug resistance acquired during cancer therapy (Fig. 5C, upper panel).